This classification of BC depends on the presence or absence of some biomarkers such as the estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2), which are used to diagnose and guide the adjuvant treatment options for BC. This evidence concerns the gene PGR and breast cancer.